NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $24.63 +0.15 (+0.61%) As of 01:23 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pacira BioSciences Stock (NASDAQ:PCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pacira BioSciences alerts:Sign Up Key Stats Today's Range$24.20▼$24.7250-Day Range$23.00▼$27.6252-Week Range$18.80▼$27.66Volume133,134 shsAverage Volume672,138 shsMarket Capitalization$981.75 millionP/E Ratio70.22Dividend YieldN/APrice Target$29.83Consensus RatingHold Company Overview Pacira BioSciences, Inc. is a pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s therapies are intended to help manage acute and chronic pain while supporting efforts to reduce reliance on opioid medications. Pacira’s principal product is EXPAREL, an extended-release formulation of bupivacaine used for postsurgical pain management and regional analgesia. The company also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain, and iovera, a device-based treatment that uses targeted cold therapy to temporarily block peripheral nerves and reduce pain. Founded as Pacira Pharmaceuticals, the company changed its name to Pacira BioSciences in 2020 to reflect its broader focus on innovative pain therapies. Its products are primarily marketed in the United States through hospitals, ambulatory surgery centers, physicians and other healthcare providers. Frank D. Lee serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Pacira BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScorePCRX MarketRank™: Pacira BioSciences scored higher than 65% of companies evaluated by MarketBeat, and ranked 257th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 3 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialPacira BioSciences has a consensus price target of $29.83, representing about 21.1% upside from its current price of $24.63.Amount of Analyst CoveragePacira BioSciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth21.21% Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 21.21% in the coming year, from $1.98 to $2.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 70.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 70.22, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.39.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.64% of the float of Pacira BioSciences has been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 16.95, which indicates bearish sentiment.Change versus previous monthShort interest in Pacira BioSciences has recently increased by 0.43%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentPacira BioSciences has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pacira BioSciences this week, compared to 4 articles on an average week.MarketBeat Follows1 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $70,619.00 in company stock.Percentage Held by Insiders6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCRX Stock News HeadlinesBrokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $29.83September 16 at 3:45 AM | americanbankingnews.comLeerink Partners Initiates Coverage on Pacira BioSciences (NASDAQ:PCRX)September 11, 2026 | americanbankingnews.comSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares.September 18 at 1:00 AM | Behind the Markets (Ad)Leerink Partners initiates coverage of Pacira BioSciences at market performSeptember 10, 2026 | msn.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 9, 2026 | globenewswire.comPacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 SharesAugust 19, 2026 | insidertrades.comIs Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?August 10, 2026 | finance.yahoo.comPacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth PlatformAugust 8, 2026 | seekingalpha.comSee More Headlines PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $25.88 at the start of the year. Since then, PCRX stock has decreased by 4.8% and is now trading at $24.63. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Tuesday, August, 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. Read the conference call transcript. When did Pacira BioSciences IPO? Pacira BioSciences (PCRX) raised $64 million in an initial public offering on Wednesday, February 2nd 2011. The company issued 4,250,000 shares at $14.00-$16.00 per share. Who are Pacira BioSciences' major shareholders? Pacira BioSciences' top institutional investors include Wellington Management Group LLP (1.41%), Bank of New York Mellon Corp (0.75%), Bank of America Corp DE (0.60%) and Hennion & Walsh Asset Management Inc. (0.52%). Insiders that own company stock include Jonathan Slonin, Daryl Gaugler, Frank D Lee, Shawn Cross, Kristen Williams, Lauren Riker, Mark Froimson and Marcelo Bigal. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/04/2026Today9/18/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PCRX's financial health is in the Green zone, according to TradeSmith. PCRX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees829Year Founded2006Price Target and Rating Average Price Target for Pacira BioSciences$29.83 High Price Target$38.00 Low Price Target$25.00 Potential Upside/Downside+21.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.35 Trailing P/E Ratio70.28 Forward P/E Ratio12.42 P/E GrowthN/ANet Income$7.03 million Net Margins1.96% Pretax Margin2.37% Return on Equity9.68% Return on Assets5.30% Debt Debt-to-Equity Ratio0.54 Current Ratio5.04 Quick Ratio3.94 Sales & Book Value Annual Sales$726.41 million Price / Sales1.35 Cash Flow$3.81 per share Price / Cash Flow6.46 Book Value$16.11 per share Price / Book1.53Miscellaneous Outstanding Shares39,860,000Free Float37,311,000Market Cap$980.36 million OptionableOptionable Beta0.26 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PCRX) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
